netFormulary NHS
NHS Bath and North East Somerset, Swindon and Wiltshire CCG
Royal United Hospitals Bath NHS Foundation Trust
Great Western Hospitals NHS Foundation Trust
Salisbury NHS Foundation Trust
 Search
 Results

Looking for Adalimumab found 20 matches

Formulary items 3 matches
Non-formulary items 1 match
   
Open monograph to display formulary status BNF Category
  Adalimumab  (Imraldi®Amgevita®Humira®)
(Injection)
Gastro-intestinal system - Drugs affecting the immune response - 01.05.03
  Adalimumab  (Imraldi®Amgevita®Humira®)
(Injection)
Musculoskeletal and joint diseases - Cytokine modulators - 10.01.03
  Adalimumab  (Imraldi® Amgevita® Humira®)
(Dermatology)
Skin - Drugs affecting the immune response - 13.05.03
 
Non Formulary BNF Category
  Adalimumab  (Imraldi®Amgevita® Humira®)
(Ophthalmology)
Eye - Other anti-inflammatory preparations - 11.04.02


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section NICE TA146 Adalimumab for the treatment of adults with psoriasis (13.05.03)
link in drug section NICE TA187: Crohn’s disease - infliximab and adalimumab  (01.05.03)
link in drug section NICE TA187: Crohns disease - infliximab & adalimumab (01.05.03)
link in drug section NICE TA195 August 2010: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (10.01.03)
link in drug section NICE TA195 August 2010: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (10.01.03)
link in subsection NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab (10.01.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis  (01.05.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis (01.05.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis  (01.05.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
link in drug section NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (10.01.03)
link in drug section NICE TA375 January 2016: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in subsection NICE TA375: Rheumatoid arthritis - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept (10.01.03)
link in drug section NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa (13.05.03)
link in drug section NICE TA455 : Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (13.05.03)


 

netFormulary